Clinical trial

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study

Name
3011/22
Description
In this project, the investigators intend to start a prospective registry for patients with newly diagnosed Philadelphia-negative ALL from 16 years old and above in participating centers, provided that all patients will be treated with the same regimen (a pediatric regimen BFM-based incorporating peg-asparaginase). All diagnostic/follow-up (after induction and consolidation blocks) samples will be centrally biobanked at Instituto do Cancer do Estado de Sao Paulo. The main goal of this study is to examine whether the implementation of a pediatric protocol under a prospective registry can increase event-free survival (EFS) and overall survival (OS) of newly diagnosed patients in the participating centers.
Trial arms
Trial start
2023-09-05
Estimated PCD
2028-06-01
Trial end
2030-06-01
Status
Recruiting
Treatment
Prednisone
60 mg/m2 D1 to D21
Arms:
Eligible patients
Vincristin
1.5 mg/m2 D1, D8, D15 and D22
Arms:
Eligible patients
Daunorubicin
40 mg/m2 D1, D8, D15 and D22
Arms:
Eligible patients
Peg-asparaginase
2000 UI/m2 D12 and D26
Arms:
Eligible patients
Intrathecal Suspension
MTX 12 mg, Dexamethasone 2 mg, Cytarabine 60 mg D1, D8, D15, D22, D29
Arms:
Eligible patients
Cyclophosphamide
1000 mg/m2 D36 and D64
Arms:
Eligible patients
Cytarabine
75 mg/m2 D36 to D39, D43 to D46, D50 to D53 and D57 to D60
Arms:
Eligible patients
Mercaptopurine
30 mg/m2 D36 to D63 and D1 to D56 of consolidation
Arms:
Eligible patients
Methotrexate
3.000 mg/m2 D8, D22, D36 and D50
Arms:
Eligible patients
Doxorubicin
30 mg/m2 D1 and D22
Arms:
Eligible patients
Size
180
Primary endpoint
Overall survival (OS)
4 years
Eligibility criteria
Inclusion Criteria: Patients between 16 and 50 years-old with newly diagnosed ALL, negative for Philadelphia chromosome not previously treated (except for hydroxyurea, corticosteroids, or intrathecal chemotherapy) with 20% or more lymphoblasts in bone marrow or peripheral blood. Exclusion Criteria: * Burkitt leukemia * Prior myeloproliferative disease * Philadelphia chromosome positivity through whichever methodology (RT-PCR, FISH, or conventional karyotype) * ECOG\>2 (appendix 3) * Total bilirubin\>2x upper limit of normal (ULN) * Transaminases\>5x ULN * Creatinine\>2,5 mg/dl * Positive serology for HIV or HTLV * Heart failure NYHA Class III or IV (appendix 4) * Severe psychiatric disorder which prevents adequate compliance * Prior treatment with intravenous chemotherapy * Refusal to participate in the study * Down syndrome
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': True, 'targetDuration': '2 Years', 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'All bone marrow or peripheral blood samples from diagnosis are going to be stored in a registered biobank. From bone marrow, DNA, RNA (Trizol) and mononuclear cryopreserved cells are going to be stored after Ficoll separated centrifugation. From peripheral blood, only DNA/RNA from buffy coat.'}, 'enrollmentInfo': {'count': 180, 'type': 'ESTIMATED'}}
Updated at
2023-09-08

1 organization

6 products

4 drugs

4 indications

Drug
R-CHOP
Indication
MRD
Product
Vincristin
Product
Cytarabine